Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4630

Sort by

Sort Order Select

Journal Articles

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Blood (2021) 138 (4): 331–343.

https://doi.org/10.1182/blood.2020010438

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

What can Heraclitus tell us about AML?

Arnold Ganser

Blood (2021) 137 (20): 2719–2720.

https://doi.org/10.1182/blood.2021011264

Published: 2021

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

Zemin Ren, Marcel Spaargaren, Steven T. Pals

Blood (2021) 137 (13): 1713–1718.

https://doi.org/10.1182/blood.2020008188

Published: 2021

Journal Articles

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Blood (2021) 137 (9): 1192–1195.

https://doi.org/10.1182/blood.2020008346

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Andrea J. Darzi, Samer G. Karam, Rana Charide, Itziar Etxeandia-Ikobaltzeta, Mary Cushman, Michael K. Gould, Lawrence Mbuagbaw, Frederick A. Spencer, Alex C. Spyropoulos, Michael B. Streiff, Scott Woller, Neil A. Zakai, Federico Germini, Marta Rigoni, Arnav Agarwal, Rami Z. Morsi, Alfonso Iorio, Elie A. Akl, Holger J. Schünemann

Blood (2020) 135 (20): 1788–1810.

https://doi.org/10.1182/blood.2019003603

Published: 2020

Includes: Supplemental data

Journal Articles

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Christoph R. Kimmich, Tobias Terzer, Axel Benner, Tobias Dittrich, Kaya Veelken, Alexander Carpinteiro, Timon Hansen, Hartmut Goldschmidt, Anja Seckinger, Dirk Hose, Anna Jauch, Stefan Wörner, Jörg Beimler, Carsten Müller-Tidow, Ute Hegenbart, Stefan O. Schönland

Blood (2020) 135 (18): 1517–1530.

https://doi.org/10.1182/blood.2019003633

Published: 2020

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Martin Stanulla, Hélène Cavé, Anthony V. Moorman

Blood (2020) 135 (4): 252–260.

https://doi.org/10.1182/blood.2019000813

Published: 2020

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Blood (2019) 134 (21): 1796–1801.

https://doi.org/10.1182/blood.2019001321

Published: 2019

Journal Articles

Elevated Serum Soluble Interleukin-2 Receptor Level Is a Useful Prognostic Factor for Disease-Specific Overall Survival in Patients with Newly Diagnosed Follicular Lymphoma before Initiation of Treatment

Blood (2019) 134 (Supplement_1): 3985.

https://doi.org/10.1182/blood-2019-126399

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

A Rise in Plasma Coagulability during the First 3 Months Following Provoked Venous Thromboembolism Is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Marisol Betensky, MDMPH, Ernest Amankwah, PhD, Stephanie Brandal, Allen Everett, MD, Neil A Goldenberg, MD PhD

Blood (2019) 134 (Supplement_1): 2424.

https://doi.org/10.1182/blood-2019-131821

Published: 2019

Journal Articles

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Blood (2019) 134 (Supplement_1): 5423.

https://doi.org/10.1182/blood-2019-125806

Published: 2019

Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 5492.

https://doi.org/10.1182/blood-2019-129324

Published: 2019

Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Blood (2019) 134 (Supplement_1): 5343.

https://doi.org/10.1182/blood-2019-126594

Published: 2019

Journal Articles

Association of Insurance Status and Marital Status with Outcomes of Patients with Chronic Lymphocytic Leukemia: A Population-Based Study

Yi Miao, MD PhD, Wei Xu, MD PhD, Lei Fan, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 5459.

https://doi.org/10.1182/blood-2019-127756

Published: 2019

Journal Articles

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

Chiaki Naito, MD, Hiroaki Shimizu, MD PhD, Yuri Miyazawa, MD PhD, Takuma Ishizaki, MD PhD, Akihiko Yokohama, MD PhD, Takayuki Saito, MD PhDProf, Norifumi Tsukamoto, MD PhD, Hiroshi Handa, MD PhD

Blood (2019) 134 (Supplement_1): 5434.

https://doi.org/10.1182/blood-2019-127956

Published: 2019

NARROW

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

What can Heraclitus tell us about AML?

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria

Erdheim-Chester disease

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Elevated Serum Soluble Interleukin-2 Receptor Level Is a Useful Prognostic Factor for Disease-Specific Overall Survival in Patients with Newly Diagnosed Follicular Lymphoma before Initiation of Treatment

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

A Rise in Plasma Coagulability during the First 3 Months Following Provoked Venous Thromboembolism Is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Association of Insurance Status and Marital Status with Outcomes of Patients with Chronic Lymphocytic Leukemia: A Population-Based Study

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only